Emergent BioSolutions Inc. revised earnings guidance for the year 2022. For the year, the company expects revised total revenues to be in the range of $1,050 million to $1,100 million compared to previously expected total revenues to be in the range of $1,150 million to $1,250 million. Net loss to be in the range of $217 million to $189 million.